< previous issue
next issue >
Moving forward to meet new challenges
Barton, S; Williams, Ig
Simplification: is it sufficient?
Cartledge, Jonathan D
Why switch from protease inhibitors (PI) to non-nucleoside reverse transcriptase inhibitors (NNRTI)?
What are the perceived advantages and disadvantages of non-nucleoside reverse transcriptase inhibitors as first-line therapy?
Efavirenz therapy in drug users
Clarke, Sm; Mulcahy, Fm